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Abstract: A significant portion of patients diagnosed with vitelliform macular dystrophy (VMD)
do not carry causative mutations in the classic VMD genes BEST1 or PRPH2. We therefore
performed a mutational screen in a cohort of 106 BEST1/PRPH2-negative VMD patients in two
genes encoding secreted interphotoreceptor matrix proteoglycans-1 and -2 (IMPG1 and IMPG2). We
identified two novel mutations in IMPG1 in two simplex VMD cases with disease onset in their
early childhood, a heterozygous p.(Leu238Pro) missense mutation and a homozygous c.807 + 5G
> A splice site mutation. The latter induced partial skipping of exon 7 of IMPG1 in an in vitro
splicing assay. Furthermore, we found heterozygous mutations including three stop [p.(Glu226*),
p.(Ser522*), p.(Gln856*)] and five missense mutations [p.(Ala243Pro), p.(Gly1008Asp), p.(Phe1016Ser),
p.(Tyr1042Cys), p.(Cys1077Phe)] in the IMPG2 gene, one of them, p.(Cys1077Phe), previously
associated with VMD. Asymptomatic carriers of the p.(Ala243Pro) and p.(Cys1077Phe) mutations
show subtle foveal irregularities that could characterize a subclinical stage of disease. Taken together,
our results provide further evidence for an involvement of dominant and recessive mutations in
IMPG1 and IMPG2 in VMD pathology. There is a remarkable similarity in the clinical appearance of
mutation carriers, presenting with bilateral, central, dome-shaped foveal accumulation of yellowish
material with preserved integrity of the retinal pigment epithelium (RPE). Clinical symptoms tend to
be more severe for IMPG1 mutations.
Keywords: vitelliform macular dystrophy; IMPG1; IMPG2; interphotoreceptor matrix; optical
coherence tomography
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1. Introduction
The interphotoreceptor matrix proteoglycans-1 and -2, also known as sialoprotein associated
with cones and rods (SPACR) and SPACRCAN (a proteoglyCan related to SPACR), respectively, are
large glycosylated protein components of the insoluble interphotoreceptor matrix (IPM) [1]. The
IPM is a specialized type of extracellular matrix that surrounds the photoreceptor inner and outer
segments and the apical processes of the retinal pigment epithelium (RPE). It serves several important
functions, including communication between photoreceptors, RPE and Müller cells, by regulating
trafficking of signaling molecules, nutrients and metabolites and the maintenance of retinal adhesion
and photoreceptor alignment [1,2] IMPG1 and IMPG2 have hyaluronan (HA) binding motifs of the
receptor for HA-mediated motility (RHAMM) type [1,3]. It is believed that secreted IMPG1 and IMPG2
bind HA and that this interaction stabilizes or modulates the IPM scaffold [1].
First evidence for an involvement of the interphotoreceptor matrix proteoglycans in the etiology
of retinal degenerative disease was given when the heterozygous c.1736T > C/p.(Leu579Pro) mutation
in the IMPG1 gene was shown to cause autosomal dominant benign concentric annular macular
dystrophy (BCAMD) in a Dutch family [4]. This phenotype is characterized by an initial parafoveal
hypopigmentation and good visual acuity which then progresses to a retinitis pigmentosa-like
manifestation. Subsequently, autosomal recessive mutations in the IMPG2 gene were identified
to be causally associated with early-onset retinitis pigmentosa (RP) [5]. The RP phenotype is frequently
accompanied by early macular abnormalities, ranging from minor pigment alterations to profound
chorioretinal atrophy [6].
Recently, mutations in IMPG1 and IMPG2 have been reported to also play a causative role in
autosomal dominant and recessive vitelliform macular dystrophy (VMD) [7,8]. Vitelliform lesions
have been defined by Gass in 1974 as bilateral, round or oval, yellow, symmetrical, singular, subretinal
lesions, typically one-third to one-half disc diameter in size [9]. Best disease is caused by dominant
(mostly missense) mutations in the BEST1 gene [10,11]. Characteristic features of this disease entity
include a diminished Arden ratio measured by electrooculography (EOG) as well as the typical egg
yolk-like vitelliform macular lesion, which can already occur during childhood [12]. In contrast,
adult-onset VMD (AVMD) becomes symptomatic not before the fourth or fifth decade of life with
a relatively mild and slowly progressive loss of central visual acuity [12,13]. Another main clinical
aspect in AVMD, and an important difference to Best disease, is a normal or only slightly subnormal
light induced rise in ocular potential [12,14]. AVMD is genetically more heterogeneous than Best
disease and has in some instances been linked to dominant mutations in BEST1 but also in the PRPH2
gene [15].
In the present study, we aimed to further investigate the role of IMPG1 and IMPG2 sequence
variations in the development of vitelliform macular disease in our large patient cohort. We have
screened the IMPG1 and IMPG2 genes in a total of 106 unrelated patients diagnosed with Best disease
or AVMD but found negative after BEST1 or PRPH2 mutation testing. We identified two patients with
novel causative mutations in the IMPG1 gene. In addition, three novel stop mutations and four novel
missense mutations as well as the c.3230G > T/p.(Cys1077Phe) mutation reported before [8] were
found in the IMPG2 gene to be heterozygously present in eight patients. To assess the pathogenicity of
these mutations we performed bioinformatic evaluation, in vitro splice assays, database searches and
family segregation as well as comparative clinical characterization of the patients.
2. Subjects and Methods
2.1. Patient Recruitment
The study included a total of 106 patients with suspected VMD or AVMD who underwent
routine genetic testing at the Institute of Human Genetics Regensburg and which were tested negative
for mutations in the coding exons/flanking intronic sequences of BEST1 and PRPH2. A positive
family history of VMD was reported for 15 cases, 46 individuals had a negative family history and
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no further information on the familial status of retinal degeneration was available for 45 patients.
Seven unaffected family members were available for carrier testing. In accordance with the German
Genetic Diagnostics Act written informed consent for genetic analysis was obtained from all subjects.
This study adhered to the tenets of the Declaration of Helsinki. The study was also approved by the
Ethics Committee of the University Regensburg, Germany (ID 17-514-104, date of approval 24.03.2017).
2.2. Clinical and Functional Ophthalmological Evaluation
Clinical, imaging, and electrophysiological findings were available and reviewed for ten index
patients carrying mutations in the IMPG1 or IMPG2 gene as well as for seven family members.
Age at initial diagnosis corresponds to the patient´s first visit to the respective University eye clinic in
Regensburg, Bonn, Freiburg, Köln, Tübingen and Berlin, where the diagnosis of vitelliform macular
dystrophy was established. Best-corrected visual acuity (VA) was assessed with standard charts under
standard clinic conditions and results were transferred into logarithm of the Minimum Angle of
Resolution (logMAR).
Electrooculograms (EOG) were recorded in six of ten index patients according to the standards of
the International Society of Clinical Electrophysiology of Vision (ISCEV) [16]. A light peak-to-dark
trough ratio of <1.5 was defined as abnormally low, of >2.0 as normal, of between 1.5 and 2.0 as
borderline, in line with the ISCEV recommendations [16]. Moreover, in six of ten patients, multifocal
electroretinograms (mfERG) were conducted following ISCEV standards [17].
Multimodal retinal imaging included color fundus photography, obtained with the Zeiss FF450+ or
Visucam (Carl Zeiss Meditec AG, Jena, Germany) and spectral domain-optical coherence tomography
(SD-OCT) as well as fundus autofluorescence (FAF) imaging, performed with a combined Heidelberg
Retina Angiograph and SD-OCT Spectralis device (Heidelberg Engineering, Heidelberg, Germany).
2.3. Molecular Analysis
For DNA extractions, ethlylenediaminetetraacetic acid (EDTA) peripheral blood samples were
obtained from all patients and family members. Next-generation sequencing (NGS) was performed
using the ION TorrentTM semiconductor technology (Thermo Fisher Scientific, Dreieich, Germany)
upon multiplex-PCR amplification of the gene fragments by exon flanking oligonucleotide primer pairs
(sequences available upon request) using the QIAGEN Multiplex PCR Master Mix (Qiagen, Hilden,
Germany). In brief, the multiplexed PCR reactions of each patient were pooled after quantification
in the MultiNA Shimadzu system (Shimadzu Biotech, Duisburg, Germany) and processed using the
Ion Xpress™ Plus Fragment Library kit (Thermo Fisher Scientific, Dreieich, Germany) according to
the manufacturers recommendations. The barcoded DNA libraries were purified with AMPure beads
(Beckman Coulter, Krefeld, Germany) and the resulting library concentration was determined using an
Agilent 2100 bioanalyzer (Agilent, Waldbronn, Germany). The emulsion PCR was carried out on the Ion
OneTouch™ 2 System and the samples were loaded on a 318 Ion Torrent™ System Chip and sequenced
with an ION Personal Genome Machine (Thermo Fisher Scientific, Dreieich, Germany). NGS data
were analyzed with the CLC Genomics Workbench (CLC bio, Aarhus, Denmark). The mean coverage
for the amplicons ranged from 56× to 5420×, with all bases sequenced at least 34×. Potentially
disease-relevant variants were confirmed by Sanger chain-terminating dideoxynucleotide sequencing.
2.4. Bioinformatics Analysis
Variants were classified as recommended by the American College of Medical Genetics and
Genomics (ACMG) standards and guidelines and the Association for Molecular Pathology (AMP)
Clinical Practice Guidelines. The recommendations were based on population data, computational data
and previous publications. Variant frequencies were taken from the Browser of the Exome Aggregation
Consortium (ExAC), variants with a minor allele frequency (MAF) > 0.005 were excluded from further
analysis. Rare missense mutations were tested for disease relevance by prediction algorithms of the
programs MutationTaster, SIFT and PolyPhen-2. When at least two of the three programs predicted
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a pathogenic effect, the variants were classified as “likely pathogenic”. Stop mutations were classified
as pathogenic. Intronic and synonymous variants were further analyzed for a potential effect on correct
splicing by using the interface provided by the software package Alamut (Interactive Biosoftware,
Rouen, France, Alamut Visual 2.7.1) which combines five algorithms (SpliceSiteFnder, MaxEntScan,
NNSPLICE, GeneSplicer and Human Splicing Finder). All tools provide prediction scores for the
normal and the mutant allele.
2.5. Minigene Assay
Functional consequences of IMPG1 splicing variant c.807 + 5G > A was analyzed with the
pSPL3b-based exon trapping system. Briefly, exon 7 of the IMPG1 gene was PCR amplified from
genomic DNA of patient #2 and control using a 7:1 ratio of Taq:Pfu polymerase and oligonucleotide
primer pairs flanked with restriction sites for NotI and BamHI (5’-GCG GCC GCG CCT TCA TAA TCC
ACT TCT TGA-3’; 5’-GGA TCC GGG CCC ATT GTA ATT TTG GT-3’) and cloned into the pSPL3b
vector (kindly provided by Dr. M. Gessler, University Würzburg, Germany). HEK293 cells were
transfected in duplicate with 3 µg of construct DNA using TransIT®-LT1 Transfection Reagent (Mirus,
Madison, WI, USA), harvested after 48 hours and total RNA was extracted using RNeasy Micro Kit
(Qiagen, Hilden, Germany). RT-PCR was performed with the RevertAid™ H First Strand cDNA
Synthesis Kit (Thermo Fisher Scientific, Waltham, MA, USA) and a pSPL3-specific SD6 (5’-TCT GAG
TCA CCT GGA CAA CC-3’) and SA4 (5’-CAC CTG AGG AGT GAA TTG GTC G-3’) primer pair
in combination with oligonucleotide primers for the housekeeping gene ACTB (5’-GAC ATC CGC
AAA GAC CTG TA-3’; 5’-CAG GAG AGC AAT GAT CTT GA-3’). PCR products were separated by
electrophoresis on a 2% agarose gel, excised, cloned and Sanger sequenced.
3. Results
3.1. Patients with Mutations Identified in the IMPG1 Gene
Mutational analysis of the IMPG1 gene identified putative causative mutations in two families
(Table 1). Patient #1 of the German family 13-501 carries a heterozygous c.713T > C nucleotide change
in exon 7 of the IMPG1 gene that leads to a p.(Leu238Pro) amino acid substitution in the SEA I domain
(Sperm protein, Enterokinase and Agrin) of the IMPG1 protein and is predicted to be pathogenic
by all three algorithms used in the in silico analysis. At the age of 13, patient #1 showed reduced
visual acuity with 0.2 and 0.1 logMAR on the right and left eye, respectively. The fundus of both eyes
revealed central RPE abnormalities with foveal detachment (images not available). Patient #1 is the
only affected member in the family. Data on ophthalmological examination or genetic testing of the
parents of patient #1 were not available.
A second IMPG1 mutation, c.807 + 5G > A, was found in patient #2 of the consanguineous Turkish
family 11-151 in a homozygous state (Table 1). Homozygosity was confirmed by segregation analysis
in the genomic DNA of the parents. The intronic c.807 + 5G > A nucleotide substitution resides
within in the conserved 5’ splice site of exon 7 and is predicted to weaken the donor splice site by
20%. The analysis of cDNA derived from HEK293 cells transfected with a construct containing the
c.807 + 5G > A mutation, revealed aberrant pre-mRNA splicing; exon 7 was skipped in about half
of the transcripts leading to a 194 bp as well as the 335 bp reverse transcription (RT)-PCR product
amplified in controls (Figure 1). An additional faint band of ~270 bp of unknown origin was seen in
cells transfected with the mutant construct. The in vitro splice assay thus confirms the bioinformatic
prediction of missplicing due to the c.807 + 5G > A variant that likely leads to nonsense-mediated
mRNA decay (NMD) of the aberrant mRNA.
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Table 1. Mutations in IMPG1 and IMPG2 in patients with vitelliform macular dystrophy.
Family ID Patient ID Gender Exon Nucleotide MAF a Status Effect
In Silico Analysis
Class PMID
MutT b SIFT c PP2 d Splicing e
IMPG1
13–501 #1 M 7 c.713T > C - het p.(Leu238Pro) dc (0.94) del (0.01) p (0.93) - lp -
11–151 #2 M 7 c.807 + 5G > A - hom splicing, p.? n.a. n.a. n.a. −20.6% p -
IMPG2
8–572 #3 F 7 c.676G > T - het p.(Glu226*) n.a. n.a. n.a. - p -
9–399 #4 M 7 c.727G > C - het p.(Ala243Pro) dc (0.9) tol (0.07) p (0.98) - lp -
8–206 #5 M 13 c.1565C > G - het p.(Ser522*) n.a. n.a. n.a. - p -
8–453 #6 M 13 c.2566C > T - het p.(Gln856*) n.a. n.a. n.a. - p -
6–225 #7 F 15 c.3023G > A 8 × 10−6 het p.(Gly1008Asp) dc (1.0) del (0) p (0.99) −8.7% lp -
6–75 #8 M 15 c.3047T > C - het p.(Phe1016Ser) dc (1.0) del (0) p (0.99) - lp -
9–274 #9 M 15 c.3125A > G - het p.(Tyr1042Cys) dc (1.0) del (0) p (0.99) - lp -
8–553 #10 F 15 c.3230G > T - het p.(Cys1077Phe) dc (1.0) del (0) p (0.98) +3.6% lp 25085631
PMID = pubmed ID; a Minor allele frequency (MAF) in total population, ExAC database in the public domain. b disease causing (dc), polymorphism (p). The probability value is given in
brackets. A value close to 1 indicates a high ‘security’ of the prediction. c deleterious (del), tolerated (tol). Score ranges from 0 to 1. The amino acid substitution is predicted damaging if
the score is ≤ 0.05, and tolerated if the score is > 0.05. d HumVar model, benign (b), possibly damaging (pd), probably damaging (p). e Splicing predictions at nearest natural junction,
combines results from SpliceSiteFinder-like, MaxEntScan, NNSPLICE, GeneSplicer, Human Splice Finder.
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isolated from these cells was reverse transcriptase (RT)-PCR amplified using pSPL3b-specific primers 
SD6 and SA4 (indicated by arrows). Schematic illustration of the splice products separated by gel 
electrophoresis is depicted on the right. The c.807 + 5G > A mutation leads to partial skipping of 
IMPG1 exon 7. RT-PCR amplification of ACTB served as control. 
Patient #2 was initially diagnosed with vitelliform macular dystrophy at the age of 2 (Table 2). 
During an eight year follow-up period the boy demonstrated fluctuating visual acuity of ~0.2 
logMAR in both eyes. Electrophysiology at the age of 10 revealed normal findings in mfERG and a 
borderline to slightly abnormally low Arden Ratio in EOG measurements (Table 2). Color fundus 
images showed a singular, vitelliform lesion in the central macula of both eyes, but otherwise normal 
fundus features (Figure 2A). The area of the vitelliform lesion increased over the 4-year follow-up 
period and corresponding SD-OCT scans revealed a bilateral, central, dome-shaped foveal 
detachment of the neurosensory retina (Figure 2B). Hyperreflective material underneath was 
reabsorbed during follow-up and has left behind an optically empty cavity. Photoreceptors 
demonstrated an elongation of outer segments. Bruch’s membrane and RPE maintained its classical 
reflectivity and seemed well preserved (Figure 2B). Corresponding FAF imaging showed circular 
hyperfluorescence which decreased in the course of disease (Figure 2C). Both heterozygous 35- and 
40-year-old parents of patient #2 are clinically asymptomatic with full visual acuity and regular 
findings in multimodal retinal imaging (data not shown). 
 
Figure 2. Multimodal retinal imaging in patient #2 with homozygous c.807 + 5G > A mutation in 
IMPG1. (A) Color fundus images of right (OD) and left (OS) eye acquired at the age of six and ten 
years reveal bilateral, yellowish vitelliform lesions with a granular aspect and no satellite drusen, 
which seem stable during these years of follow-up. (B) Corresponding horizontal SD-OCT scans 
through the fovea at the age of 6 years demonstrate a central, dome-shaped foveal detachment of the 
neurosensory retina with some solid material underneath. The latter is resorbed during follow-up, 
leading to an optically empty cavity at the age of ten. Photoreceptor outer segments seem to be 
elongated. Bruch’s membrane and RPE maintain classical reflectivity and seem well preserved. (C) 
Corresponding FAF images show bilateral, central, circular hyperfluorescence, which decreases 
during follow-up (in line with the resorption of the solid material).  
Figure 1. In vitro splicing assay of the IMPG1 mutation c.807 + 5G > A. Genomic DNA fragments
containing exon 7 and flanking intronic sequences from patient #2 carrying the c.807 + 5G > A mutation
and a control individual were cloned into pSPL3b and overexpressed in HEK293 cells. RNA isolated
from these cells was reverse transcriptase (RT)-PCR amplified using pSPL3b-specific primers SD6 and
SA4 (indicated by arrows). Schematic illustration of the splice products separated by gel electrophoresis
is depicted on the right. The c.807 + 5G > A mutation leads to partial skipping of IMPG1 exon 7. RT-PCR
amplification of ACTB served as control.
Patient #2 was initially diagnosed with vitelliform macular dystrophy at the age of 2 (Table 2). During
an eight year follow-up period the boy demonstrated fluctuating visual acuity of ~0.2 logMAR in both
eyes. Electrophysiology at the age of 10 revealed normal findings in mfERG and a borderline to slightly
abnormally low Arden Ratio in EOG measurements (Table 2). Color fundus images showed a singular,
vitelliform lesion in the central macula of both eyes, but otherwise normal fundus features (Figure 2A).
The area of the vitelliform lesion increased over the 4-year follow-up period and corresponding SD-OCT
scans revealed a bilateral, central, dome-shaped foveal detachment of the neurosensory retina (Figure 2B).
Hyperreflective material underneath was reabsorbed during follow-up and has left behind an optically
empty cavity. Photoreceptors demonstrated an elongation of outer segments. Bruch’s membrane
and RPE maintained its classical reflectivity and seemed well preserved (Figure 2B). Corresponding
FAF imaging showed circular hyperfluorescence which decreased in the course of disease (Figure 2C).
Both heterozygous 35- and 40-year-old parents of patient #2 are clinically asymptomatic with full visual
acuity and regular findings in multimodal retinal imaging (data not shown).
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Table 2. Summary of clinical information on patients with mutations in IMGP1 and IMPG2.
Family ID a Patient ID Age b [years] Visual Acuity [logMAR] Electrophysiology
EOG [Arden ratio] Multifocal ERG
OD OS OD OS OD OS
IMPG1
13–501 #1 16 (12) 0.2 0.1 NA NA NA NA
11-151 #2
6 (2) 0.1 0.1 1.6 5.0 normal normal
10 0.2 0.2 1.6 1.4 normal normal
IMPG2
8–572 #3 59 (57) 0.1 0.2 normal normal normal minor reduction of amplitudes in ring 1
9–399 #4 54 (47) 0.4 0.2 2.3 2.3 NA NA
8–206 #5 54 (46) 0.7 0.1 NA NA marked reduction of amplitudes in ring 1–2 marked reduction of amplitudes in ring 1–2
8–453 #6 64 (60) 0.6 0.2 1.9 1.8 NA NA
6–225 #7 43 (33) 0.1 0.1 2.2 2.2 normal normal
6–75 #8 57 (56) 0.1 0.2 NA NA minor reduction of amplitudes in ring 1 minor reduction of amplitudes in ring 1
9–274 #9 62 (62) 0.6 0.2 NA NA NA NA
8–553 #10 70 (64) 0.4 0.3 2.5 4.1 marked reduction of amplitudes in ring 1–2 marked reduction of amplitudes in ring 1–2
logMAR = logarithm of the Minimum Angle of Resolution; EOG = electrooculogram; ERG = electroretinogram; OD = right eye; OS = left eye; NA = not available; a Patients have been
sorted by ascending cDNA position of the respective mutation (see Table 1). b Age at last available examination (age at initial diagnosis).
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3.2. Patients with Mutations Identified in the IMPG2 Gene
Eight patients were found to carry heterozygous mutations in the IMPG2 gene including three
stop mutations [p.(Glu226*), p.(Ser522*) and p.(Gln856*)] and five missense mutations [p.(Ala243Pro),
p.(Gly1008Arg), p.(Phe1016Ser), p.(Tyr1042Cys) and p.(Cys1077Phe)] (Figure 3). The latter missense
mutations all have strong in silico evidence to affect IMPG2 protein function (Table 1). Except for
mutation c.3023G > A/p.(Gly1008Asp), which was found once in 120.878 control alleles, none of the
other seven sequence changes is listed in the ExAC database (Table 1).
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Figure 3. Sche atic representation of the IMPG2 protein and mutations. The IMPG2 protein is depicted
as a white bar with the respective protein domains indicated in ifferent colours. Mutations identified
i retinit s pigmentosa patients are shown above, mutations identified in patients with other forms of
r tinal dystrophy are shown below the IMPG2 protein. Those in bold are mutations identified in VMD
pa ents described in this study. Mutations with an expected effect on the protein level but without
a reliable prediction of the conseque ce (e.g., splice mutations) are indicated as p.?.
For all eight index patients carr i t s I PG2 mutations clinical information was
v ilable. All individuals were sympto atic, slo ly progres ing central vis on loss over
years an id not receive any specific t. ean age at init al diagnosi was 53.1 years
(range 33–64 years, Table 2), only one ati nger than 45 years at init al diagnosis.
Mean visual acuity was 0.4 logMAR in the right eye (range 0.7–0.1) and 0.2 logMAR in the left
eye (range 0.3–0.1). All patients revealed visual acuity ≤0.3 logMAR in the better eye (Table 2).
Electrophysiological findings were available for seven of the eight patients (Table 2). The light
peak-to-dark trough ratio measured by EOG was borderline in one and within the normal range in three
patients. Multifocal ERG measurements revealed normal findings in one patient (#7), the remaining
four patients showed reduced amplitudes in the central rings of at least one eye (Table 2). Patient
#4 had regular full-field ERG measurements available. Multimodal retinal imaging via color fundus
photography, SD-OCT and FAF revealed highly similar findings in all eight index patients (Figure 4).
One set of eyes (both eyes of #3, #4, #5 and #8, #6 left eye, #7 right eye) showed differently sized,
singular, brown-yellowish vitelliform lesions in the central macula on color fundus images (Figure 4A).
Corresponding SD-OCT scans (when available), visualized a foveal detachment of the neurosensory
retina with hyperreflective material located above the seemingly preserved Bruch’s membrane/RPE
(Figure 4B). Matching FAF images demonstrated hyperfluorescence (Figure 4C). Both, SD-OCT and
FAF findings corresponded to the vitelliform material seen on color fundus images.
In a second set of eyes (#10 both eyes, #7 and #9 left eyes), the subretinal material was partially or
completely resorbed, leaving behind a dome-shaped, optically empty cavity underneath the elevated
neurosensory retina in SD-OCT scans (Figure 4B). Bruch’s membrane/RPE was still well preserved and
m intai d its classical reflectivity. A correspo ding enlarged central hypofluorescence was observed
by FAF (Figure 4C).
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Figure 4. Multimodal retinal imaging of eight VMD patients with heterozygous mutations in IMPG2.
Patients have been sorted by ascending cDNA position of the respective mutation (see Table 1).
(A) Color fundus images of right (OD) and left (OS) eyes reveal bilateral, round, yellowish vitelliform
lesions of different sizes with a granular aspect and no satellite drusen, or central atrophy (#6 OD
and #9 OD). (B) Corresponding SD-OCT visualizes foveal detachment of the neuros nsory retina
with hyp r flective material (corresponding to the vitelliform material) located above he seemingly
preserved Bruch’s membrane/RPE (#3 both eyes, #4 both eyes, #6 OS, #7 OD). The solid material is in
some cases partially or fully resorbed, leaving behind a dome-shaped optically empty cavity (#7 OS, #9
OS, #10 both eyes) or central atrophy (#6 OD, #9 OD). (C) FAF shows either central hyperfluorescence
corresponding to the vitelliform material (#3 both eyes, #4 both eyes, #5 both eyes, #6 OS, #9 OS),
or hypofluorescence corresponding to an optically empty cavity (#10 both eyes) or central atrophy (#6
OD, #9 OD). NA = images not available.
Finally, in a third set of ey s, color fundus images as well as SD- OCT scans demonstrated central
atrophy with loss of RPE in the right eyes of patients #6 and #9 which matched hypofluorescence
seen by FAF (Figure 4A–C). As expected, visual acuity in these two eyes was markedly reduced
to 0.6 logMAR (Table 2). Disease severity as defined by age of onset, visual acuity or lesions seen
by retinal imaging was not associated with a specific type of mutation (nonsense versus missense
mutation) in our patients. Importantly, associated drusen-like lesions were not detectable in the foveal
zone or at the posterior pole.
3.3. Ophthalmological and Genetic Analysis of Relatives of Patients with IMPG2 Mutations
C rrier status of IMGP2 mutations and ophthalmic findings were obta ed for five individuals
from four different families (Figure 5). The 29-year old asymptomatic son of index patien #3 (family
8-572, #3-1), had normal visual acuity and regular SD-OCT results consistent with his non-carrier
status of the c.676G > T/p.(Glu226*) mutation of his mother. The sister of index patient #3 was
reported to have a “similar” maculopathy but was not available for genetic or ophthalmic testing.
The 11 year younger sister of #4 (family 9-399), age 44 (#4-1), carries the same heterozygous c.727G
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> C/p.(Ala243Pro) mutation in exon 7 of the IMPG2 gene as her affected brother. Despite being
asymptomatic, she had a slightly reduced visual acuity to 0.1 logMAR in her left eye due to a marked
dome-shaped, foveal detachment of the neurosensory retina visualized by SD-OCT with some solid
material above the seemingly intact RPE. A similar, but smaller lesion was observed in the SD-OCT
scans of her right eye. Both asymptomatic sons of index patient #9 (family 9-274), age 40 (#9-1) and 42
(#9-2) respectively, inherited the c.3125A > G/p.(Tyr1042Cys) mutation in exon 15 of the IMPG2 gene
from their father. The older son showed a slight reduction of visual acuity to 0.1 logMAR in his right
eye. SD-OCT scans revealed no abnormalities of the central retina in both brothers. Finally, patient
#10 (family 8-553) has transmitted the c.3230G > T/p.(Cys1077Phe) mutation to her 31 year old son
(#10-1) who complained about reading problems. Visual acuity was reduced to 0.2 logMAR in the
right eye, corresponding to a minor, but noticeable dome-shaped foveal detachment with material
above the RPE and defects at the photoreceptor inner segment/outer segment junction (ellipsoid zone)
in SD-OCT. His left eye showed full visual acuity but SD-OCT revealed mild subfoveal accumulation
of hyperreflective material without RPE or photoreceptor abnormalities. Taken together, SD-OCT
findings in the offspring of patients with VMD that inherited the heterozygous IMPG2 mutations from
the affected relative indicate the very early subfoveal accumulation of debris that might progress to
larger vitelliform lesions or atrophy later in life.
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Figure 5. Genetics and clinical data of family members of VMD patients with heterozygous IMPG2
mutations. (A) Pedigrees of families with mutations in the IMPG2 gene. Patients with pathological
findings are indicated by filled symbols. Family members with available clinical information and
SD-OCT data [horizontal scans through the fovea shown in (B)] are marked with arrows, age in years
is given below. A minor, dome-shaped foveal neuroretinal detachment filled with subretinal material
above the RPE is observed for relatives in family 9-399 (OS > OD) and 8-553 (note the minor defects
at the photoreceptor inner segment/outer segment junction (ellipsoid zone) in OD). Corresponding
visual acuity (VA) results in logMAR are given below.
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4. Discussion
In this study we have identified a series of novel mutations in the IMPG1/IMPG2 genes
and provide supportive evidence for their causativity in the development of vitelliform macular
dystrophy. Patients with IMPG1/IMPG2 mutations described here reveal strikingly similar phenotypic
characteristics, including retinal lesions which can be divided into presumably consecutive stages:
(i) singular vitelliform lesions in the central macula with detachment of the neurosensory retina in
SD-OCT, with hyperreflective material located above the seemingly preserved Bruch’s membrane/RPE;
(ii) resorption of the hyperreflective material leaving behind a dome-shaped, optically empty cavity;
alternatively, the foveal cavity formed by retinal detachment may become successively filled with
material; (iii) collapse of the cavity and central retinal atrophy with loss of RPE. This stage of disease
lead to the most pronounced loss of visual acuity.
Previous reports of clinical features in IMPG-associated VMD [7,8] are largely consistent with our
findings including mild to moderate vision impairment, normal or borderline EOG and regular or
slightly abnormal ERG findings as well as the appearance of the vitelliform macular lesions in color
fundus images and FAF with subretinal material located strictly above the preserved RPE as depicted
by SD-OCT. All our patients had bilateral singular, unifocal deposits without associated drusen-like
lesions at the posterior pole. It has been proposed that satellite drusen-like lesions in the foveal zone
are characteristic for IMPG1-linked VMD [8]. Since the ages of onset in the patients with satellite
drusen ranged between 27 and 54 and the patients at examination were thus significantly older than
our two patients with IMPG1-mutations (they are now in their teens), it remains to be seen whether
they will also develop similar drusen-like abnormalities in adulthood.
An earlier study reported on a c.713T > G mutation in exon 7 of the IMPG1 gene in three families
with autosomal dominant VMD [7]. Here, we have detected a similar mutation affecting c.713,
a thymine to guanine exchange, in a simplex case of VMD. Both mutations lead to the substitution
of the moderately conserved, hydrophobic amino acid leucine at position 238 to either a positively
charged arginine [p.(Leu238Arg)] or to a cyclic proline [p.(Leu238Pro)]. Modelling of the SEAI domain
of IMPG1 indicated that an arginine at position 238 destabilizes the protein [7] and mutations which
result in an introduction of a proline are known to significantly affect protein stability [18]. Thus,
the current finding of a second missense mutation affecting amino acid p.(Leu238) in a patient with
VMD supports the causative role of defective IMPG1 molecules in disease via an as yet unknown
dominant-negative effect or haploinsufficiency.
The second novel mutation in the IMPG1 gene described in this study, a c.807 + 5G > A mutation
in intron 7 causing aberrant splicing of the IMPG1 mRNA, was found in a young Turkish boy in
a homozygous state. Another splice mutation in intron 7, c.807 + 1G > T affecting the canonical GT
donor splice sequence, has previously been described in a consanguineous Italian family [7]. Affected
individuals of this family showed multifocal vitelliform deposits in addition to the prominent central
lesion. Since the fundus images of these patients were taken at the age of 29 and 33, it will be interesting
to observe whether our 13 year old patient will develop similar lesions when disease progresses with
age. Interestingly, heterozygous carriers of the c.807 + 1G > T mutation show a slightly decreased
EOG Arden ratio and tiny extramacular deposits in fundus examination suggesting that heterozygous
carriers of the c.807 + 1G > T variant display a mild subclinical phenotype due to haploinsufficiency.
Both heterozygous 35 and 40 year old parents of patient #2 are clinically asymptomatic with full
visual acuity and regular findings in multimodal retinal imaging (data not shown). Our finding that
a significant fraction of pre-mRNAs harboring the c.807 + 5G > A mutation are correctly spliced
suggests that the level of functional IMPG1 is sufficient to prevent even subclinical abnormalities in
heterozygous carriers.
Homozygous or compound heterozygous nonsense, frameshift or splice site mutations in the
IMPG2 gene causing loss of IMPG2 function have repeatedly been described in patients with autosomal
recessive retinitis pigmentosa (RP) (Figure 3, upper panel). These mutations are scattered throughout
the gene but are preferentially found in the N-terminal part (23-276 aa), two central regions (530-560
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aa and 758-805 aa) and the C-terminal part (964-1212 aa) of IMPG2. In addition, a homozygous
p.(Phe124Leu) mutation was reported in a patient with mild maculopathy [5], a p.(Arg137Pro) mutation
in a patient with Goldmann-Favre syndrome [19] and a heterozygous p.(Cys1077Phe) mutation in
a patient with VMD [8]. These sequence variants as well as the stop and missense mutations found
in our VMD patients are located in the N-terminal, the first central and C-terminal “hotspots”. The
VMD-associated stop mutations p.(Glu226*), p.(Ser522*) and p.(Gln856*) in exon 7 and 13 of the IMPG2
gene are likely targets for nonsense mediated decay (NMD) or lead to truncated proteins with impaired
function and are therefore considered null mutations. So far, the evidence for a possible VMD causing
effect of IMPG2 haploinsufficiency is based on the absence of the respective stop mutations in a large
control population and the typical IMPG-linked phenotype of our three index patients. A recent
report about patients with IMPG2-associated RP revealed that three quarters of the patients (n = 13)
had profound macular abnormalities including bull’s eye maculopathy and macular atrophy [6].
These macular lesions are described as an early generalized loss of the outer retinal layers prior to
RPE degeneration and are thus very different from the foveal subretinal deposits seen in our VMD
patients. Nevertheless, it would be important to study the heterozygous parents of these and other
IMPG2-associated RP patients for subtle ophthalmological abnormalities such as minor foveal deposits.
The same c.3230G > T/p.(Cys1077Phe) IMPG2 mutation detected in the 70-year old female index
patient of family 8-553 has previously been reported in a 44-year old male with progressive bilateral
vitelliform lesions and his asymptomatic 22-year old son [8]. SD-OCT scans of both of the son’s
eyes revealed an abnormal thin hyperreflective line between the ellipsoid and outer segment-RPE
interdigitation lines which was interpreted as a preclinical stage of IMPG2-VMD [8]. In support of an
autosomal-dominant inheritance of the p.(Cys1077Phe) mutation, we observed distinct foveal lesions
in the 31-year old son of patient #10 consisting with an accumulation of material above the RPE and
mild visual impairment. Similarly, the sister of index patient #4 who is a heterozygous carrier of the
familial c.727G > C/p.(Ala243Pro) mutation in IMPG2 exon 7 and showed subclinical deposits above
the RPE in the foveal zone and slightly decreased visual acuity.
Both sons of family 9-274, who inherited the heterozygous c.3125A > G/p.(Tyr1042Cys) mutation
in exon 15 of the IMPG2 gene from their father, were 40 and 42 years of age when ophthalmologically
examined. They were then asymptomatic and revealed regular retinal structures in SD-OCT. Their
father was diagnosed with VMD not before the age of 62 and they may develop retinal disease later in
life consistent with a rather late disease onset for symptomatic carriers of known C-terminal IMPG2
missense mutations.
Four of the five VMD-associated missense mutations in the IMPG2 gene are located within a stretch
of 80 amino acids in the two epidermal growth factor (EGF)-like motifs at the N-terminal vicinity of
a highly hydrophobic putative transmembrane spanning domain. The p.(Gly1008Asp) amino acid
exchange affects one of the four consensus sequences of glycosaminoglycan (GAG) attachment sites in
IMPG2, namely Ser1007-Gly-(acidic) and may influence protein interaction that is important for the
establishment and stability of the IPM matrix.
Six conserved cysteine residues in each of the two tandem EGF-like motifs of IMPG2 likely form
the characteristic EGF-like disulfide bridges required for stability of EGF-like motifs [20]. IMPG2
mutations p.(Tyr1042Cys) and p.(Cys1077Phe) add or replace a cysteine residue in the EGF-like domain
and may thus interfere with interchain disulfide bonding. Disruption of the disulfide bond pattern
of EGF-like domains plays a major role in the pathogenesis of several inherited diseases [21,22].
Unravelling the molecular processes linking mutations in the IMPG1 and IMPG2 genes to retinal
degeneration will be an important task for future experiments.
5. Conclusions
Taken together, this study supports the role of mutations in the genes encoding interphotoreceptor
matrix proteins IMPG1 and IMPG2 in the development of vitelliform macular dystrophy and
emphasizes the need to perform diagnostic testing of these genes especially in VMD patients without
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EOG abnormalities. Screening for larger structural alteration in the IMPG1 and IMPG2 genes by
copy number variation (CNV) analysis might even increase the number of VMD cases associated
with defects in these two genes. Finally, our report also highlights the importance of monitoring
asymptomatic carriers for subclinical foveal abnormalities to further shed light on the inheritance
pattern, penetrance and expressivity of IMPG1/IMPG2 mutations.
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